However, ramucirumab, a mAb targeting VEGFR-2, demonstrated efficacy in the RAINBOW and REGARD studies, confirming that the VEGF/VEGFR pathway is also a crucial therapeutic target in gastric cancer. This evidence concerns the gene KDR and gastric cancer.